Literature DB >> 11328677

Comparison of the radical trapping ability of PBN, S-PPBN and NXY-059.

K R Maples1, F Ma, Y K Zhang.   

Abstract

The nitrones alpha-phenyl-N-tert-butyl nitrone (PBN), sodium 2-sulfophenyl-N-tert-butyl nitrone (S-PBN) and disodium 2,4-disulfophenyl-N-tert-butyl nitrone (NXY-059) are neuroprotective in a variety of rodent models. The objective of the current studies was to compare the ability of PBN, S-PBN, and NXY-059 to form radical adducts and to prevent salicylate oxidation in an aqueous system. For the electron spin resonance (ESR) studies, hydroxyl radicals were generated with ultraviolet (UV) light and hydrogen peroxide. Secondary radicals were then produced by the addition of methanol, ethanol, isopropanol, dimethylsulfoxide, tetrahydrofuran or 1,4-dioxane. In addition, competition spin trapping studies were performed using PBN-alpha-(13) C and either S-PBN or NXY-059. In the salicylate studies, PBN, S-PBN and NXY-059 were compared to a variety of other antioxidants and reference compounds (cysteine, glutathione, ascorbate, uric acid, Tempo, Trolox, and Tirilizad) for their ability to prevent 2,3- and 2,5-dihydroxybenzoic acid formation induced by hydroxyl radical generating systems. All 3 nitrones trapped carbon- and oxygen-centered radicals to produce ESR-detectable radical adducts. Each nitrone also prevented salicylate oxidation, with PBN being the most effective. The ability of these 3 nitrones to prevent salicylate oxidation resembled that of most of the other compounds tested.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11328677     DOI: 10.1080/10715760100300351

Source DB:  PubMed          Journal:  Free Radic Res        ISSN: 1029-2470


  16 in total

1.  CeeTox™ Analysis of CNB-001 a Novel Curcumin-Based Neurotrophic/Neuroprotective Lead Compound to Treat Stroke: Comparison with NXY-059 and Radicut.

Authors:  Paul A Lapchak; James M McKim
Journal:  Transl Stroke Res       Date:  2011-03       Impact factor: 6.829

Review 2.  Nitrones as therapeutics.

Authors:  Robert A Floyd; Richard D Kopke; Chul-Hee Choi; Steven B Foster; Sabrina Doblas; Rheal A Towner
Journal:  Free Radic Biol Med       Date:  2008-08-29       Impact factor: 7.376

3.  Selective gelatinase inhibitor neuroprotective agents cross the blood-brain barrier.

Authors:  Major Gooyit; Mark A Suckow; Valerie A Schroeder; William R Wolter; Shahriar Mobashery; Mayland Chang
Journal:  ACS Chem Neurosci       Date:  2012-07-30       Impact factor: 4.418

Review 4.  Nitrone-related therapeutics: potential of NXY-059 for the treatment of acute ischaemic stroke.

Authors:  Kirk R Maples; A Richard Green; Robert A Floyd
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

5.  The use of the Chandler loop to examine the interaction potential of NXY-059 on the thrombolytic properties of rtPA on human thrombi in vitro.

Authors:  N J Mutch; N R Moore; C Mattsson; H Jonasson; A R Green; N A Booth
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

6.  Neuroprotection by S-PBN in hyperglycemic ischemic brain injury in rats.

Authors:  Maria Molnar; Fredrik Lennmyr
Journal:  Ups J Med Sci       Date:  2010-08       Impact factor: 2.384

7.  Effects of NXY-059 in experimental stroke: an individual animal meta-analysis.

Authors:  P M W Bath; L J Gray; A J G Bath; A Buchan; T Miyata; A R Green
Journal:  Br J Pharmacol       Date:  2009-04-27       Impact factor: 8.739

Review 8.  Neuroprotective effects of free radical scavengers in stroke.

Authors:  Chen X Wang; Ashfaq Shuaib
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 9.  Novel approaches for the delivery of therapeutics in ischemic stroke.

Authors:  Saeideh Nozohouri; Ali Ehsan Sifat; Bhuvaneshwar Vaidya; Thomas J Abbruscato
Journal:  Drug Discov Today       Date:  2020-01-21       Impact factor: 7.851

Review 10.  Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, neuroprotection possibly.

Authors:  A R Green
Journal:  Br J Pharmacol       Date:  2007-12-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.